

DATE:

July 25, 2005

SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6963.US.01

SERIAL NO.

10/524,376

APPLICANT

Joel Melnick, et al.

FILING DATE

February 15, 2005

GROUP

(not assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Berweck, S., et al., "Cardiac mortality prevention in uremic patients", <i>Clinical Nephrol</i> 2000 Germany, 53(Suppl1):S80-S85 (2000)
C2	Cada, D.J., et al., "Paricalcitol Injection and Ribavirin/Interferon Alfa-2b", <i>Hosp. Pharm., Lippincott, Philadelphia, US</i> , 34(3):303-338 (1999)
C3	Drueke & McCarron, "Paricalcitol as Compared with Calcitriol in Patients Undergoing Hemodialysis", <i>N Engl J Med</i> , 349(5):496-499 (2003)
C4	Keller & Potter, "Predictors of Mortality in Outpatient Geriatric Evaluation and Management Clinic Patients", <i>Jour of Gerontology</i> , 49(6):M246-M251 (1994)
C5	Lanska & Kryscio, "Geographic distribution of hospitalization rates, case fatality, and mortality from stroke in the United States", <i>Neurology</i> , 44(8):1541-1550 (1994)
C6	Lindberg, J., et al., "A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease", <i>Clinical Nephrology</i> , 56(4):315-323 (2001)
C7	Llach, F., "Paricalcitol: An Updated Review and Guidelines for Use", <i>Dialysis and Transplantation</i> 2001 US, 30(10):654-664 (2001)

EXAMINER

/Sahar Javanmard/


DATE CONSIDERED

08/07/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./



DATE:

July 25, 2005

SHEET 2 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6963.US.01

SERIAL NO.

10/524,376

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Joel Melnick, et al.

FILING DATE

February 15, 2005

GROUP

(not assigned)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
							YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C8	Marco, M.P., et al., "Influence of Vitamin D Receptor Gene Polymorphisms on Mortality Risk in Hemodialysis Patients", <i>Amer Jour of Kidney Dis</i> , 38(5) :965-974 (2001)
C9	Martin, K.J., et al., "Paricalcitol Dosing According to Body Weight or Severity of Hyperparathyroidism: A Double-Blind, Multicenter, Randomized Study", <i>Amer Jour of Kidney Dis.</i> , 38(5)(Suppl5) :S57-S63 (2001)
C10	Salusky & Goodman, "Cardiovascular calcification in end-stage renal disease", <i>Nephrol Dial Transplant</i> , 17 :336-339 (2002)
C11	Szelachowska, M., et al., "Samoistna Postać zespołu Fanconiego u osoby dorosłej", <i>US Natl Libr of Med (NLM)</i> , 1(6) :414-416 (1996)
C12	Tarantino, G., et al., "The Efficacy of Oral and Intravenous Calcitriol Pulses Therapy in Hemodialysis Patients: Four Years Follow-Up", <i>Nephrology Dialysis Transp.</i> , 16(6) :A130 (2001)
C13	Teng, M., et al., "Survival Benefit of Zemplar Compared with Calcijex among Dialysis Patients", <i>Journ of the Amer Soc of Nephrology</i> , 13 (prog & Abstracts Issue) : A461A (2002)
C14	Teng, M., et al., "Survival of Patients Undergoing Hemodialysis with paricalcitol or Calcitriol Therapy", <i>The New Engl Jour of Med.</i> , 349(5) :446-456 (2003)

EXAMINER

/Sahar Javanmard/

DATE CONSIDERED

08/07/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./